Apimeds Pharmaceuticals US (APUS) Accumulated Expenses (2023 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Accumulated Expenses came in at $918649.0 in Q4 2025, up 55.39% YoY from $591191.0 in Q4 2024, and up 679.18% on a QoQ basis from $117899.0 in Q1 2025.
Apimeds Pharmaceuticals US (APUS) Accumulated Expenses (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 3 years of Accumulated Expenses data on file, last reported at $918649.0 in Q4 2025.
- Quarterly Accumulated Expenses rose 55.39% year-over-year to $918649.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $918649.0 (up 55.39% YoY) and the FY2025 annual result came in at $918649.0, up 55.39% from the prior year.
- Accumulated Expenses improved to $918649.0 in Q4 2025, from $117899.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $918649.0 in Q4 2025 to a low of $68878.0 in Q4 2023.
- A 3-year average of $424154.2 and a median of $354545.0 in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses soared 758.32% — and 2025, when it surged 55.39%.
- Tracing APUS's Accumulated Expenses over 3 years: stood at $68878.0 in 2023, then soared by 758.32% to $591191.0 in 2024, then surged by 55.39% to $918649.0 in 2025.
- The last three Accumulated Expenses figures came in at $918649.0 (Q4 2025), $117899.0 (Q1 2025), and $591191.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Apimeds Pharmaceuticals US | 7.12 Mn | 7.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 918,649.00 |
| Mar 31, 2025 | 117,899.00 |
| Dec 31, 2024 | 591,191.00 |
| Dec 31, 2023 | 68,878.00 |